Payment overview · 2025
General Payments
$918.00
44 reported records · 12 companies
Healthcare provider profile · identity verified
Edward John Luschinski
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · EASTON, MD · NPI 1205447448
Verified facts
What the public records show
CMS Open Payments records show Edward John Luschinski received $918.00 in general payments during 2025 across 44 reported records.
Boston Scientific Corporation accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Movantik, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Belbuca by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nucynta by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $226.31 | 24.6% | 11 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $170.12 | 18.5% | 6 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $129.61 | 14.1% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.62 | 9.2% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$71.62 | 7.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.77 | 5.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.08 | 4.0% | 2 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $35.78 | 3.9% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $32.35 | 3.5% | 2 | 2025 |
| INTERNATIONAL REHABILITATIVE SCIENCES, INC | Unresolved — no canonical attribution shown | $28.63 | 3.1% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $28.06 | 3.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $23.05 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $918.00 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $180.61 | 9 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $170.12 | 6 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $129.61 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.62 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.77 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.77 | 3 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $45.70 | 2 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $35.78 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| RS-4i Plus with Intersperse Normalized: rs 4i plus with intersperse |
Device | INTERNATIONAL REHABILITATIVE SCIENCES, INC | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 76 | exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 55 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 1776 | 235 |
| Gabapentin | Gabapentin | 1334 | 213 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1190 | 184 |
| Pregabalin | Pregabalin | 633 | 96 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 605 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 599 | 116 |
| Tramadol Hcl | Tramadol Hcl | 547 | 97 |
| Tizanidine Hcl | Tizanidine Hcl | 479 | 87 |
| Methylprednisolone | Methylprednisolone | 369 | 219 |
| Morphine Sulfate Er | Morphine Sulfate | 262 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 196 | 66 |
| Trazodone Hcl | Trazodone Hcl | 174 | 32 |
| Methocarbamol | Methocarbamol | 155 | 40 |
| Ibuprofen | Ibuprofen | 153 | 35 |
| Celecoxib | Celecoxib | 149 | 24 |
| Lidocaine | Lidocaine | 133 | 39 |
| Baclofen | Baclofen | 111 | 23 |
| Meloxicam | Meloxicam | 106 | 25 |
| Prednisone | Prednisone | 96 | 59 |
| Buprenorphine Hcl | Buprenorphine Hcl | 95 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 23 |
| Ondansetron Odt | Ondansetron | 88 | 19 |
| Hydromorphone Hcl | Hydromorphone Hcl | 83 | 12 |
| Morphine Sulfate | Morphine Sulfate | 81 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | suppressed |
| Belbuca | Buprenorphine Hcl | 76 | 13 |
| Fentanyl | Fentanyl | 64 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 60 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 18 |
| Naproxen | Naproxen | 60 | 21 |
| Oxycontin | Oxycodone Hcl | 58 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 16 |
| Movantik | Naloxegol Oxalate | 55 | 15 |
| Carisoprodol | Carisoprodol | 52 | suppressed |
| Linzess | Linaclotide | 52 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 17 |
| Methadone Hcl | Methadone Hcl | 49 | suppressed |
| Topiramate | Topiramate | 48 | 11 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 16 |
| Diazepam | Diazepam | 42 | 19 |
| Buprenorphine | Buprenorphine | 41 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 41 | 18 |
| Lisinopril | Lisinopril | 41 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 39 | 12 |
| Azithromycin | Azithromycin | 39 | 29 |
| Famotidine | Famotidine | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Symproic | Naldemedine Tosylate | 33 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 31 | 12 |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 18 |
| Xtampza Er | Oxycodone Myristate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Etodolac | Etodolac | 27 | suppressed |
| Losartan Potassium | Losartan Potassium | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Nucynta | Tapentadol Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Furosemide | Furosemide | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 22 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Ztlido | Lidocaine | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Metaxalone | Metaxalone | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 17 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Lyrica | Pregabalin | 14 | suppressed |
| Etodolac Er | Etodolac | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $918.00 · 44 records | Boston Scientific Corporation | BOTOX, Belbuca, INCEPTIV, INTELLIS ADAPTIVESTIM, Intracept, JOURNAVX, KRYSTEXXA, MOVANTIK, NURTEC ODT, QULIPTA, QUTENZA, RS-4i Plus with Intersperse, SUBLOCADE, SYNCHROMEDII, Senza, UBRELVY, WaveWriter Alpha Prime 16, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error